Anne Phelan
Chief Scientific Officer, BenevolentAI
As BenevolentAI’s CSO, Anne Phelan is responsible for all aspects of drug discovery from therapeutic area selection through to target identification. She is passionate about building high-functioning and cohesive teams with equal gender representation at every level that are committed to delivering life-changing medicines to the clinic. Before joining BenevolentAI, she held roles at Mission Therapeutics and Pfizer as executive vice president head of research and COO head of pharmacology respectively. With a BSc and PhD in Genetics from the University of Liverpool, UK, Phelan’s areas of expertise range from drug discovery, molecular pharmacology, and plate based screening, to genomics, CRO outsourcing, and clinical project leadership.
“The idea that I could apply my experience in genetics and molecular pharmacology to solving some of the key unanswered questions in the most challenging human diseases, to identify drugs with the potential to directly benefit patients, is hugely motivational. It’s like solving the ultimate puzzle, with a huge impact on patients’ quality of life.”
Read our 2020 interview with Anne Phelan
